<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610580</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1840-HV-109</org_study_id>
    <nct_id>NCT04610580</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of 2 Oral Formulations of ALXN1840</brief_title>
  <official_title>A Phase 1, Randomized, 2-period, 2-sequence, Crossover With Parallel-group Extension, Open-label Study to Compare the Relative Bioavailability of 2 Oral Formulations of ALXN1840 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in&#xD;
      healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-way crossover study consisting of 2 dosing periods assessing a test and&#xD;
      reference formulation of ALXN1840. A dose-proportionality parallel group design extension&#xD;
      period will be conducted following completion of the two-way crossover period of the study&#xD;
      and will assess 5 different ascending doses of ALXN1840. There will be at least a 14-day&#xD;
      washout following doses between Periods 1 and 2 and also at least a 14-day washout following&#xD;
      the dose in Period 2 and the following dose in the Dose-Proportionality Extension Period.&#xD;
&#xD;
      Safety will be assessed throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2021</start_date>
  <completion_date type="Actual">April 26, 2021</completion_date>
  <primary_completion_date type="Actual">March 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a 2-period, 2-sequence, crossover study with a parallel group extension.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo) and Plasma Ultrafiltrate (PUF) Mo</measure>
    <time_frame>Period 1: up to 336 hours postdose and Period 2: up to 336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) For Plasma Total Mo and PUF Mo</measure>
    <time_frame>Period 1: up to 336 hours postdose and Period 2: up to 336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) For Plasma Total Mo and PUF Mo</measure>
    <time_frame>Period 1: up to 336 hours postdose and Period 2: up to 336 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized Cmax For Plasma Total Mo and PUF Mo</measure>
    <time_frame>up to 336 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized AUCt For Plasma Total Mo and PUF Mo</measure>
    <time_frame>up to 336 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized AUCinf For Plasma Total Mo and PUF Mo</measure>
    <time_frame>up to 336 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Crossover ALXN1840 Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover ALXN1840 Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1840.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1840.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1840</intervention_name>
    <description>ALXN1840 will be administered orally.</description>
    <arm_group_label>Crossover ALXN1840 Sequence 1</arm_group_label>
    <arm_group_label>Crossover ALXN1840 Sequence 2</arm_group_label>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 1</arm_group_label>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 2</arm_group_label>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 3</arm_group_label>
    <arm_group_label>Parallel Dose-proportionality Extension: ALXN1840 Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No clinically significant history or presence of electrocardiogram findings&#xD;
&#xD;
          -  Body weight ≥50 to ≤100 kilograms (kg) and body mass index 18 to &lt;32 kg/meter squared&#xD;
             for all participants&#xD;
&#xD;
          -  Willing and able to follow protocol-specified contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinical and/or laboratory disorders&#xD;
&#xD;
          -  Abnormal blood pressure, defined as supine blood pressure ≤90/60 millimeters of&#xD;
             mercury (mmHg) or &gt;140/90 mmHg&#xD;
&#xD;
          -  Lymphoma, leukemia, or any malignancy within the past 5 years&#xD;
&#xD;
          -  Alanine aminotransferase, aspartate aminotransferase, or total bilirubin &gt; upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Serum copper or serum ceruloplasmin below lower limit of normal&#xD;
&#xD;
          -  Hemoglobin &lt;130 grams (g)/liter (L) for males and hemoglobin &lt;115 g/L for females&#xD;
&#xD;
          -  Significant allergies&#xD;
&#xD;
          -  Smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Healthy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

